320367-13-3 Usage
Description
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is used in the treatment of type 2 diabetes mellitus. It works by stimulating the pancreas to secrete insulin when blood sugar levels are high, helping to move sugar from the blood into other body tissues for energy. Additionally, Lixisenatide slows the emptying of the stomach and decreases appetite, further aiding in blood sugar control.
Uses
Used in Pharmaceutical Industry:
Lixisenatide is used as a treatment for type 2 diabetes to help control blood sugar levels. It is used in conjunction with diet and exercise and works by stimulating the pancreas to secrete insulin when needed, as well as slowing stomach emptying and reducing appetite.
Lixisenatide is not used as a treatment for type 1 diabetes, where the body does not produce insulin. It is also not used as a replacement for insulin in people with diabetes who require insulin therapy.
History
Lixisenatide (brand name Lyxumia), has been available since 2013 in many other countries. It is now the fifth GLP-1 receptor agonist to be approved in the United States.
Indications
Both Adlyxin and Soliqua 100/33 are FDA-approved as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Soliqua 100/33 is indicated specifically in those inadequately controlled on basal insulin (less than 60 units daily) or lixisenatide.
Mechanism of action
Lixisenatide is a GLP-1 receptor agonist that works by increasing glucose-dependent insulin release, decreasing glucagon secretion, and slowing gastric emptying.Insulin glargine works through regulation of glucose metabolism. Specifically, insulin lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Pharmacology
Lixisenatide acts as an agonist at the GLP-1 receptor. In the pancreas, this agonism results in increased glucose-stimulated insulin exocytosis by beta islet cells. This produces a reduction in blood glucose due to increased glucose uptake by tissues 1. GLP-1 receptor activation in the GI tract results in delayed gastric emptying which is thought to mediate the effects of lixisenatide on postprandial blood glucose.
Clinical Use
#N/A
Safety
The most common adverse reactions associated with lixisenatide during clinical trials were hypoglycemia, allergic reactions, nausea, nasopharyngitis, upper respiratory tract infection, and headache.
Drug interactions
Potentially hazardous interactions with other drugs
Anti-arrhythmics: concentration of lomitapide
possibly increased by dronedarone - avoid.
Antibacterials: concentration of lomitapide possible
increased by clarithromycin and erythromycin -
avoid.
Anticoagulants: increases warfarin concentration.
Antifungals: concentration of lomitapide possibly
increased by ketoconazole and triazoles - avoid.
Antivirals: concentration of lomitapide possibly
increased by darunavir, fosamprenavir, indinavir,
lopinavir, ritonavir, saquinavir, telaprevir and
tipranavir - avoid.
Bicalutamide: separate lomitapide and bicalutamide
administration by 12 hours.
Calcium channel blockers: concentration of
lomitapide possibly increased by diltiazem and
verapamil - avoid.
Lipid lowering agents: reduce simvastatin dose by
50% if used together
Metabolism
As a peptide, lixisenatide is eliminated through
glomerular filtration, followed by tubular reabsorption
and subsequent metabolic degradation, resulting in
smaller peptides and amino acids, which are reintroduced
in the protein metabolism.
Check Digit Verification of cas no
The CAS Registry Mumber 320367-13-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,0,3,6 and 7 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 320367-13:
(8*3)+(7*2)+(6*0)+(5*3)+(4*6)+(3*7)+(2*1)+(1*3)=103
103 % 10 = 3
So 320367-13-3 is a valid CAS Registry Number.
